Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
NovoCure Limited stock logo
NVCR
NovoCure
$14.28
-20.0%
$15.53
$9.82
$18.92
$2.07B0.931.41 million shs4.85 million shs
Penumbra, Inc. stock logo
PEN
Penumbra
$316.88
+0.2%
$324.67
$221.26
$362.41
$12.44B0.71400,264 shs672,787 shs
Insulet Corporation stock logo
PODD
Insulet
$145.76
+1.6%
$165.33
$140.63
$354.88
$9.94B1.131.44 million shs2.86 million shs
Teleflex Incorporated stock logo
TFX
Teleflex
$126.97
+1.6%
$129.54
$100.18
$139.67
$5.53B0.82571,252 shs557,448 shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
NovoCure Limited stock logo
NVCR
NovoCure
-20.00%-19.37%-16.05%+20.91%-15.00%
Penumbra, Inc. stock logo
PEN
Penumbra
+0.22%-0.52%-2.92%-5.77%+23.30%
Insulet Corporation stock logo
PODD
Insulet
+1.56%-2.30%-5.72%-35.82%-51.70%
Teleflex Incorporated stock logo
TFX
Teleflex
+1.51%-1.63%-4.54%+20.59%+7.85%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
NovoCure Limited stock logo
NVCR
NovoCure
$14.28
-20.0%
$15.53
$9.82
$18.92
$2.07B0.931.41 million shs4.85 million shs
Penumbra, Inc. stock logo
PEN
Penumbra
$316.88
+0.2%
$324.67
$221.26
$362.41
$12.44B0.71400,264 shs672,787 shs
Insulet Corporation stock logo
PODD
Insulet
$145.76
+1.6%
$165.33
$140.63
$354.88
$9.94B1.131.44 million shs2.86 million shs
Teleflex Incorporated stock logo
TFX
Teleflex
$126.97
+1.6%
$129.54
$100.18
$139.67
$5.53B0.82571,252 shs557,448 shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
NovoCure Limited stock logo
NVCR
NovoCure
-20.00%-19.37%-16.05%+20.91%-15.00%
Penumbra, Inc. stock logo
PEN
Penumbra
+0.22%-0.52%-2.92%-5.77%+23.30%
Insulet Corporation stock logo
PODD
Insulet
+1.56%-2.30%-5.72%-35.82%-51.70%
Teleflex Incorporated stock logo
TFX
Teleflex
+1.51%-1.63%-4.54%+20.59%+7.85%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
NovoCure Limited stock logo
NVCR
NovoCure
2.38
Hold$26.8688.08% Upside
Penumbra, Inc. stock logo
PEN
Penumbra
2.18
Hold$361.3314.03% Upside
Insulet Corporation stock logo
PODD
Insulet
2.74
Moderate Buy$240.7865.19% Upside
Teleflex Incorporated stock logo
TFX
Teleflex
2.30
Hold$146.0014.99% Upside

Current Analyst Ratings Breakdown

Latest NVCR, PODD, TFX, and PEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2026
NovoCure Limited stock logo
NVCR
NovoCure
Reiterated RatingBuy$48.00 ➝ $46.00
6/11/2026
Insulet Corporation stock logo
PODD
Insulet
Set Price Target$219.00
6/11/2026
Insulet Corporation stock logo
PODD
Insulet
Lower Price TargetBuy$250.00 ➝ $219.00
6/11/2026
Penumbra, Inc. stock logo
PEN
Penumbra
Reiterated RatingSector Perform$374.00
6/8/2026
Insulet Corporation stock logo
PODD
Insulet
Set Price Target$216.00
6/8/2026
Teleflex Incorporated stock logo
TFX
Teleflex
UpgradeNeutralOverweight$140.00 ➝ $160.00
6/1/2026
NovoCure Limited stock logo
NVCR
NovoCure
UpgradeSell (E+)Sell (D-)
6/1/2026
Insulet Corporation stock logo
PODD
Insulet
Lower Price TargetHold$379.00 ➝ $294.00
5/28/2026
Insulet Corporation stock logo
PODD
Insulet
Lower Price TargetNeutral$175.00 ➝ $165.00
5/27/2026
Insulet Corporation stock logo
PODD
Insulet
Reiterated RatingBuy
5/27/2026
Insulet Corporation stock logo
PODD
Insulet
Reiterated RatingBuy$205.00
(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
NovoCure Limited stock logo
NVCR
NovoCure
$655.35M2.52N/AN/A$3.04 per share4.70
Penumbra, Inc. stock logo
PEN
Penumbra
$1.40B8.88$4.31 per share73.54$36.45 per share8.69
Insulet Corporation stock logo
PODD
Insulet
$2.71B3.73$6.42 per share22.70$21.54 per share6.77
Teleflex Incorporated stock logo
TFX
Teleflex
$1.99B2.82$11.38 per share11.16$70.71 per share1.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
NovoCure Limited stock logo
NVCR
NovoCure
-$136.23M-$1.53N/AN/AN/A-25.66%-50.82%-16.48%7/23/2026 (Estimated)
Penumbra, Inc. stock logo
PEN
Penumbra
$177.69M$4.3473.0150.061.9411.76%10.87%8.45%8/4/2026 (Estimated)
Insulet Corporation stock logo
PODD
Insulet
$247.10M$4.3033.9018.171.1310.44%26.87%12.01%8/6/2026 (Estimated)
Teleflex Incorporated stock logo
TFX
Teleflex
-$905.64M-$22.80N/A12.040.93-35.88%13.29%6.55%7/30/2026 (Estimated)

Latest NVCR, PODD, TFX, and PEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Teleflex Incorporated stock logo
TFX
Teleflex
$1.21$1.39+$0.18-$0.18$536.91 million$548.30 million
5/6/2026Q1 2026
Penumbra, Inc. stock logo
PEN
Penumbra
$1.06$0.82-$0.24$0.82$370.47 million$374.76 million
5/6/2026Q1 2026
Insulet Corporation stock logo
PODD
Insulet
$1.19$1.42+$0.23$1.30$729.89 million$761.70 million
4/30/2026Q1 2026
NovoCure Limited stock logo
NVCR
NovoCure
-$0.5122-$0.62-$0.1078-$0.62$167.77 million$174.06 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
Insulet Corporation stock logo
PODD
Insulet
N/AN/AN/AN/AN/A
Teleflex Incorporated stock logo
TFX
Teleflex
$1.361.07%N/AN/A N/A

Latest NVCR, PODD, TFX, and PEN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/15/2026
Teleflex Incorporated stock logo
TFX
Teleflex
quarterly$0.341.03%5/22/20265/25/20266/30/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
NovoCure Limited stock logo
NVCR
NovoCure
0.71
2.90
2.70
Penumbra, Inc. stock logo
PEN
Penumbra
0.01
6.02
3.95
Insulet Corporation stock logo
PODD
Insulet
0.71
2.49
1.81
Teleflex Incorporated stock logo
TFX
Teleflex
0.82
2.55
2.03

Institutional Ownership

CompanyInstitutional Ownership
NovoCure Limited stock logo
NVCR
NovoCure
84.61%
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%
Insulet Corporation stock logo
PODD
Insulet
N/A
Teleflex Incorporated stock logo
TFX
Teleflex
95.62%

Insider Ownership

CompanyInsider Ownership
NovoCure Limited stock logo
NVCR
NovoCure
5.52%
Penumbra, Inc. stock logo
PEN
Penumbra
2.90%
Insulet Corporation stock logo
PODD
Insulet
0.36%
Teleflex Incorporated stock logo
TFX
Teleflex
0.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,605115.82 million109.43 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
4,70039.33 million38.19 millionOptionable
Insulet Corporation stock logo
PODD
Insulet
5,40069.26 million69.02 millionOptionable
Teleflex Incorporated stock logo
TFX
Teleflex
15,50044.27 million43.96 millionOptionable

Recent News About These Companies

Teleflex announces $500M private notes offering

New MarketBeat Followers Over Time

Media Sentiment Over Time

NovoCure stock logo

NovoCure NASDAQ:NVCR

$14.28 -3.57 (-20.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$14.41 +0.13 (+0.90%)
As of 06/18/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Penumbra stock logo

Penumbra NYSE:PEN

$316.88 +0.72 (+0.23%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$317.01 +0.13 (+0.04%)
As of 06/18/2026 05:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Insulet stock logo

Insulet NASDAQ:PODD

$145.76 +2.24 (+1.56%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$146.00 +0.24 (+0.16%)
As of 06/18/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Teleflex stock logo

Teleflex NYSE:TFX

$126.97 +2.01 (+1.61%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$126.92 -0.05 (-0.04%)
As of 06/18/2026 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.